Overactive BladderBeaconNCT01369485
Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder
A study testing (VERV™ System) in people with Overactive Bladder, run by Ethicon Endo-Surgery at 14 sites in United States.
Trial summary
The purpose of this study is to evaluate the change from baseline between the active and sham treatment groups in the treatment of urgency (urinary) incontinence episodes (leaks). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Overactive Bladder
- What is being tested?
- (VERV™ System)
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 163 participants
- Where
- 14 sitesUnited States
- Study dates
- Jun 2011to Dec 2013
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Males and Females, at least 18 years of age
- Failure on primary OAB treatment, such as behavior modification or fluid/diet management, AND at least one (1) anti-cholinergic drug (unless patient was contra-indicated for anti-cholinergic use)
- Symptoms of overactive bladder for at least 6 months
- An average of one (1) or more urgency (urinary) incontinence episodes per 24-hours, over a 3-day period, confirmed by the 3-day baseline voiding diary, with a maximum of 12 urgency (urinary) incontinence episodes per 24-hours
- Dexterity and ability to place and operate the device
- Females of child-bearing capability agrees to use a reliable form of birth control for the duration of the trial
Show all 9Show fewer
- An average of eight (8) or more voids per 24-hours, over a 3-day period, confirmed by the 3-day baseline voiding diary
- Willing and capable of understanding and complying with all requirements of the protocol, including proper completion of the baseline voiding diary
- Signed and dated the IRB-approved Informed Consent document.
Who cannot join
- Dysfunctional voiding symptoms unrelated to OAB, such as clinically significant bladder outlet obstruction, and urinary retention (pvr > 100 cc)
- Morbidly obese, defined as having Body Mass Index (BMI) > 40 kg/m2
- Stress predominant mixed urinary incontinence
- Neurological disease affecting urinary bladder function, including but not limited to Parkinson's disease, multiple sclerosis, stroke, spinal cord injury and uncontrolled epilepsy.
- Pelvic surgery (such as sub-urethral sling, pelvic floor repair) within the past 6 months
- Intravesical or urethral sphincter Botulinum Toxin Type A injections within the past 12 months
Show all 19Show fewer
- Any neuromodulation therapy for overactive bladder within the past 3 months
- Failure to respond to previous neuromodulation therapy for overactive bladder
- Leading edge of any vaginal prolapse is beyond hymenel ring.
- Prior peri-urethral or transurethral bulking agent injections for bladder problems within the past 12 months.
- Any skin conditions affecting treatment or assessment of the treatment sites
- History of lower back surgery or injury that could impact placement of the patch, or where underlying scar tissue or nerve damage may impact treatment.
- Presence of an implanted electro-medical device (e.g. pacemaker, defibrillator, InterStim®, etc.), or any metallic implant in the lower back.
- Pregnant, nursing, suspected to be pregnant (by urine pregnancy method), or plans to become pregnant during the course of the study.
- Known latex allergies, or allergies or hypersensitivity to patch materials that will be in contact with the body (e.g., hydrogel, acrylic-based adhesive, polyurethane).
- Uncontrolled diabetes and/or diabetes with peripheral neuropathy.
- Current Urinary Tract Infection (UTI) or history of recurrent UTIs (>3 UTIs in the past year).
- History of lower tract genitourinary malignancies within the last 6 months or any previous pelvic radiation.
- Any clinically significant systemic disease or condition that in the opinion of the Investigator would make the patient unsuitable for the study.
Trial locations and contacts
14 sites in 1 country.
14 sites in 1 country
United States14 sites
McKay Urology
Charlotte, North Carolina, 28207
Alliance Urology Specialists, P.A.
Greensboro, North Carolina, 27403
1st Urology, PSC dba Metropolitan Urology
Jeffersonville, Indiana, 47130
Integrity Medical Research
Mountlake Terrace, Washington, 98043
Tri Valley Urology Medical Group
Murrieta, California, 92562
Carolina Urologic Research
Myrtle Beach, South Carolina, 29572
Specialists in Urology
Naples, Florida, 34102
University Urology Associates
New York, New York, 10016
Women's Health Institute of Illlinois, Ltd
Oak Lawn, Illinois, 60453
Urology Center of Florida
Pompano Beach, Florida, 33060
William Beaumont Hospital
Royal Oak, Michigan, 48073
Arizona Urologic Specialists
Tucson, Arizona, 85712-5803
GW Medical Faculty Associates
Washington D.C., District of Columbia, 20037
Wheaton Franciscan Medical Group - Milwaukee Urogynecology
Wauwatosa, Wisconsin, 53226
About this study
Official title: Multi-center, Prospective, Randomized, Double-blind, Sham-controlled Clinical Study to Evaluate Safety and Effectiveness of a Transcutaneous, High-frequency, Amplitude-modulated, Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Subjects With Overactive Bladder (OAB)
The purpose of this study is to evaluate the change from baseline between the active and sham treatment groups in the treatment of urgency (urinary) incontinence episodes (leaks).
- Conditions
- Overactive Bladder
- Being tested
- (VERV™ System), Sham version of (VERV™ System)
- Keywords
- Urinary Incontinence, Overactive Bladder, Frequency, Urgency
- Medical subject headings
- Urinary Bladder, Overactive, Urinary Incontinence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
(VERV™ System)Device
Also called Non-invasive neurostimulation device
Active electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
Sham version of (VERV™ System)Device
Also called Inactive Non-invasive neurostimulation device
Inactive (sham) electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
| Study group | Role | What they receive |
|---|---|---|
| Active Treatment group | Active comparator | VERV™ System Receives: Device: (VERV™ System) |
| Sham Treatment Group | Sham comparator | Sham version of (VERV™ System) Receives: Device: Sham version of (VERV™ System) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate Proportion of Responders Based on the Change From Baseline in Mean Urgency (Urinary) Incontinence Episodes (Leaks) Between the Active and Sham Treatment Groups
The primary objective of the randomized phase of the study is to evaluate the 12 week change from baseline in mean urgency (urinary) incontinence episodes (leaks) between the active and sham treatment groups. The mean of the number of urinary incontinence episodes over 24 hours" is defined as the mean of the number of UIEs recorded per 24 hour period for three consecutive days (via a 3-day diary).
The primary objective of the open label phase of the study is to evaluate and confirm the continued efficacy of the VERV™ System for long-term use. The primary objective was assessed with rate of responders, where responder was defined as a subject who achieved a decrease of ≥50% in mean urgency urinary incontinence episodes at 12 weeks compared to baseline.
Measured: 12 weeks (Randomized Phase) and 12 Months (Open Label)
Evaluate the Median Change From Baseline in Mean Urgency (Urinary) Incontinence Episodes (Leaks) Between the Active and Sham Treatment Groups
The primary objective of the randomized phase of the study is to evaluate the 12 week and 12 month median change from baseline in mean urgency (urinary) incontinence episodes (leaks) between treatment groups. The mean of the number of urinary incontinence episodes over 24 hours" is defined as the mean of the number of UIEs recorded per 24 hour period for three consecutive days (via a 3-day diary).
Mean urinary frequency episodes calculated for each patient during time period. The median change in frequency was then calculated for each treatment group. Distribution of changes from baseline were then assessed prospectively for normality using the Kolmogorov - Smirnoff test. Since departure from normality was actually observed in the distribution, the Wilcoxon Rank-Sum test was performed to compare the median change between treatment groups and the p-values for the test of equality of medians were reported along with the medians.
Measured: 12 weeks (Randomized Phase) and 12 Months (Open Label)
Secondary outcomes (9)
Measure Change in the Median of the Mean Urinary Frequency
Evaluate the 12 week change from baseline in median urinary frequency between the active and sham treatment groups.
Mean urinary frequency episodes calculated for each patient during time period. The median change in frequency was then calculated for each treatment group. Distribution of changes from baseline were then assessed prospectively for normality using the Kolmogorov - Smirnoff test. Since departure from normality was actually observed in the distribution, the Wilcoxon Rank-Sum test was performed to compare the median change between treatment groups and the p-values for the test of equality of medians were reported along with the medians.
Measured: 12 weeks and 12 Months
Measure Median Change in Mean Volume Per Void
Evaluate the 12 week median change from baseline in mean volume (ml) per void between the active and sham treatment groups
Measured: 12 weeks
Measure Decrease in the Median Change From Baseline in Mean Urgency Episodes
Evaluate the 12 week change from baseline in median for mean number of urgency episodes between the active and sham treatment groups.
Patients were required to complete seven 3-day voiding diaries throughout the course of the study. The voiding diary collected the following information: amount voided (in ml); urgency associated with each toileted void , approximate time of leak, and presence of urge preceding leak.The mean number of urgency episodes over 24 hours was then calculated for each patient during the observation period. The change in median for the mean of the number of urgency episodes over 24 hours) for each treatment group was then calculated.
Distribution of changes from baseline were assessed prospectively using the Kolmogorov - Smirnoff test. The Wilcoxon Rank-Sum test was performed to compare the median change between treatment groups and the p-values for the test of equality of medians were reported along with the medians.
Measured: 12 weeks
Measure Improvement in the Median of the Mean OAB-Symptom Composite Score
OAB Symptom Composite Score (OAB-SCS) is a composite symptom score of toilet voids, urgency severity and urge urinary incontinence combining the Indevus Urgency Severity Scale (IUSS) for capture of urgency severity per toilet void with 24-hour frequency and UUI episodes.
IUSS Score/void and/or UUI is assigned an OAB-SCS Point/Void: 0(none)=1, 1(mild/easily tolerated)=2, 2(moderate discomfort interfering with activities)=3, 3(severe/extreme urgency discomfort that abruptly stopped all activity or tasks)=4, UUI without void=5.
Overall OAB-SCS Score is calculated for each day by multiplying the OAB-SCS Points/Void and/or UUIs by the number of events meeting criteria and adding the individual scores together. The minimum overall OAB-SCS score in a 24 hour period would be a 1 (representing a single mild void with a OAB -SCS Point/Void score of 0). The score would increase based upon the number voids/events and overall severity each event. Medians calculated for each treatment group.
Measured: 12 weeks
Change in Median Total Health Related Quality of Life (HRQL) of OAB-q From Baseline (Screening) to Week 12
The OAB-q is validated to measure symptom bother and life impact due to OAB. It consists of an 8-item Bother Scale to assess individual symptoms and a 25-item HRQL scale that in turn consists of 4 subscales (coping-8 items, concern-7 items, sleep-5 items and social-5 items) to assess impact on life. Responses for each item in the Bother Scale range from 1 (bothered not at all by the symptom) to 6 (Bothered A Very Great Deal). Scores are then added generating an overall Bother Score (severity) ranging from 8 to 48. For HRQL, individual responses range between 1-None of the Time to a 6-All of the Time. Subscale scores range from 8-48 (coping) 7-42 (concern), 5-30 (sleep) and 5-30 (social). Subscale scores are then added to generate the HRQL ranging between 25-150. Raw HRQL scores are transformed for standardization purposes as follows: ((Highest Possible Score-Actual Raw Score)/Range of Scores)*1 00 so that scores could range from 0 (All of the Time) to 100 (None of the Time).
Measured: 12 Weeks (Randomized Phase) and 12 Months (Open Label).
Change in Patient Perception of Bladder Condition (PPBC) From Baseline (Screening Period) to Week 12 as Defined as an Improvement in Severity.
PPBC is a 6-point scale (from 'no problems at all' to 'many severe problems') describing the problem level of the bladder condition at that moment. Improvement is defined as a reduction in the number and/or severity of observed problems.
Measured: 12 Weeks (Randomized Phase) and 12 Months (Open Label Phase)
Assessment of Treatment Benefit Scale (TBS)
TBS is a patient-reported outcome comprised of a 4-point scale of checkboxes to describe the change in condition during treatment (greatly improved to worsened). Improvement was defined as a change in the patient's assessment of overall condition to improved or greatly improved over the course of treatment. Analysis was based upon the number of patients who reported an improvement in condition.
Measured: 12 Weeks
Assessment of Improvement as Measure by Overactive Bladder Satisfaction With Treatment Questionnaire (OAB-SAT)
Overall satisfaction with treatment was assessed (OAB-SAT-q) an 11 question list with multiple scaled checkboxes to allow the subject to rate the treatment with regard to satisfaction, bother from side effects, treatment endorsement, and convenience.
Measured: 12 weeks
Change Clinical Global Impressions at 12 Weeks
CGI is an Investigator assessment, which rates the severity of illness at baseline on a scale of 1 (normal, not ill at all) to 7 (Amongst the most extremely ill patients), and then rates improvement at 12 weeks on a scale of 1 (very much improved) to 10 (very much worse). The analysis was based upon the number of patients that "much" and "very much" improved.
Measured: 12 weeks (Randomized Phase) and 12 Months (Open Label Phase)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jun 2011 (estimated)
- Study startJun 2011
- Primary completionJan 2013
- Study completionDec 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Overactive BladderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 163 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ethicon Endo-Surgery
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Novella Clinical, Data & Inference, Inc.
- Responsible party
- Sponsor
- Investigators
- Michael Kennelly, MD, Principal investigator, McKay Urology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01369485
- Sponsor's protocol ID
- CI-10-0009
- Acronym
- Beacon
- Status last verified
- Sep 2014
- First submitted
- 24 May 2011
- Last updated
- 11 Sep 2014
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multi-center, Prospective, Randomized, Double-blind, Sham-controlled Clinical Study to Evaluate Safety and Effectiveness of a Transcutaneous, High-frequency, Amplitude-modulated, Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Subjects With Overactive Bladder (OAB)
- ClinicalTrials.gov ID
- NCT01369485
- Acronym / sponsor ID
- Beacon / CI-10-0009
- Conditions
- Overactive Bladder
- Keywords
- Urinary Incontinence, Overactive Bladder, Frequency, Urgency
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 163 participants (actual)
- Lead sponsor
- Ethicon Endo-SurgeryIndustry (pharma, biotech, devices)
- Collaborators
- Novella Clinical, Data & Inference, Inc.
- Study start
- Jun 2011
- Primary completion
- Jan 2013 (actual)
- Study completion
- Dec 2013 (actual)
- First posted
- 9 Jun 2011 (estimated)
- Results
- Posted 11 Sep 2014
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the change from baseline between the active and sham treatment groups in the treatment of urgency (urinary) incontinence episodes (leaks).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active Treatment group | Active comparator | Device: (VERV™ System)VERV™ System |
| Sham Treatment Group | Sham comparator | Device: Sham version of (VERV™ System)Sham version of (VERV™ System) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Males and Females, at least 18 years of age
- Failure on primary OAB treatment, such as behavior modification or fluid/diet management, AND at least one (1) anti-cholinergic drug (unless patient was contra-indicated for anti-cholinergic use)
- Symptoms of overactive bladder for at least 6 months
- An average of one (1) or more urgency (urinary) incontinence episodes per 24-hours, over a 3-day period, confirmed by the 3-day baseline voiding diary, with a maximum of 12 urgency (urinary) incontinence episodes per 24-hours
- Dexterity and ability to place and operate the device
Key exclusion criteria (19 listed)
- Dysfunctional voiding symptoms unrelated to OAB, such as clinically significant bladder outlet obstruction, and urinary retention (pvr > 100 cc)
- Morbidly obese, defined as having Body Mass Index (BMI) > 40 kg/m2
- Stress predominant mixed urinary incontinence
- Neurological disease affecting urinary bladder function, including but not limited to Parkinson's disease, multiple sclerosis, stroke, spinal cord injury and uncontrolled epilepsy.
- Pelvic surgery (such as sub-urethral sling, pelvic floor repair) within the past 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| (VERV™ System)Also: Non-invasive neurostimulation deviceActive electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete. | Device | Active Treatment group |
| Sham version of (VERV™ System)Also: Inactive Non-invasive neurostimulation deviceInactive (sham) electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete. | Device | Sham Treatment Group |
Primary outcome
Evaluate Proportion of Responders Based on the Change From Baseline in Mean Urgency (Urinary) Incontinence Episodes (Leaks) Between the Active and Sham Treatment Groups
Time frame: 12 weeks (Randomized Phase) and 12 Months (Open Label)
The primary objective of the randomized phase of the study is to evaluate the 12 week change from baseline in mean urgency (urinary) incontinence episodes (leaks) between the active and sham treatment groups. The mean of the number of urinary incontinence episodes over 24 hours" is defined as the mean of the number of UIEs recorded per 24 hour period for three consecutive days (via a 3-day diary). The primary objective of the open label phase of the study is to evaluate and confirm the continued efficacy of the VERV™ System for long-term use. The primary objective was assessed with rate of responders, where responder was defined as a subject who achieved a decrease of ≥50% in mean urgency urinary incontinence episodes at 12 weeks compared to baseline.
Evaluate the Median Change From Baseline in Mean Urgency (Urinary) Incontinence Episodes (Leaks) Between the Active and Sham Treatment Groups
Time frame: 12 weeks (Randomized Phase) and 12 Months (Open Label)
The primary objective of the randomized phase of the study is to evaluate the 12 week and 12 month median change from baseline in mean urgency (urinary) incontinence episodes (leaks) between treatment groups. The mean of the number of urinary incontinence episodes over 24 hours" is defined as the mean of the number of UIEs recorded per 24 hour period for three consecutive days (via a 3-day diary). Mean urinary frequency episodes calculated for each patient during time period. The median change in frequency was then calculated for each treatment group. Distribution of changes from baseline were then assessed prospectively for normality using the Kolmogorov - Smirnoff test. Since departure from normality was actually observed in the distribution, the Wilcoxon Rank-Sum test was performed to compare the median change between treatment groups and the p-values for the test of equality of medians were reported along with the medians.
9 secondary outcomes
Measure Change in the Median of the Mean Urinary Frequency
Time frame: 12 weeks and 12 Months
Measure Median Change in Mean Volume Per Void
Time frame: 12 weeks
Measure Decrease in the Median Change From Baseline in Mean Urgency Episodes
Time frame: 12 weeks
Measure Improvement in the Median of the Mean OAB-Symptom Composite Score
Time frame: 12 weeks
Change in Median Total Health Related Quality of Life (HRQL) of OAB-q From Baseline (Screening) to Week 12
Time frame: 12 Weeks (Randomized Phase) and 12 Months (Open Label).
Change in Patient Perception of Bladder Condition (PPBC) From Baseline (Screening Period) to Week 12 as Defined as an Improvement in Severity.
Time frame: 12 Weeks (Randomized Phase) and 12 Months (Open Label Phase)
Assessment of Treatment Benefit Scale (TBS)
Time frame: 12 Weeks
Assessment of Improvement as Measure by Overactive Bladder Satisfaction With Treatment Questionnaire (OAB-SAT)
Time frame: 12 weeks
Change Clinical Global Impressions at 12 Weeks
Time frame: 12 weeks (Randomized Phase) and 12 Months (Open Label Phase)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2014.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Overactive Bladder
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Active, not recruitingPhase 2/3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary Incontinence, Overactive Bladder Syndrome
Recruiting
UCon Treatment of Overactive Bladder (OAB) in Males
Urinary Incontinence, Urge Incontinence
Active, not recruitingObservational study
Overactive Bladder Symptoms and Urinary Incontinence In Women With Rheumatoid Arthritis
Rheumatoid Arthritis, Rheumatoid Arthritis (RA)
RecruitingObservational study
Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder
Overactive Bladder (OAB)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Kennelly, MD principal investigator
McKay Urology
14 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing (VERV™ System) in people with Overactive Bladder, run by Ethicon Endo-Surgery at 14 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 14 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 11 Sep 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate Proportion of Responders Based on the Change From Baseline in Mean Urgency (Urinary) Incontinence Episodes (Leaks) Between the Active and Sham Treatment Groups (time frame: 12 weeks (Randomized Phase) and 12 Months (Open Label)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2014.